ACLXArcellx, Inc.

$7B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63M

Gross Profit

$62M98.9% margin

Operating Income

$15M23.8% margin

Net Income

$20M31.4% margin

EPS (Diluted)

$0.38

QoQ Revenue Growth

+322.2%

Cash Flow

Operating Cash Flow

$58M

Free Cash Flow

$53M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$825M

Total Liabilities

$340M

Stockholders' Equity

$485M

Cash & Equivalents

$395M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63M	$0	—
Gross Profit	$62M	$0	—
Operating Income	$15M	-$40M	+137.5%
Net Income	$20M	-$39M	+150.9%

ACLX Q4 2023 Earnings — Arcellx, Inc. Revenue & Financial Results | Market Cap Arena